Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase.

Zheng BZ, D'Andrea SV, Hanumegowda U, Knipe JO, Mosure K, Zhuo X, Lemm JA, Liu M, Rigat KL, Wang YK, Fang H, Poronsky C, Cutrone J, Wu DR, Arunachalam PN, Balapragalathan TJ, Arumugam A, Mathur A, Meanwell NA, Gao M, Roberts SB, Kadow JF.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3294-3300. doi: 10.1016/j.bmcl.2017.06.024. Epub 2017 Jun 11.

PMID:
28633899
2.

Discovery and preclinical evaluation of potent, orally bioavailable, metabolically stable cyclopropylindolobenzazepine acylsulfonamides as thumb site 1 inhibitors of the hepatitis c virus NS5B RNA-dependent, RNA polymerase.

Hewawasam P, Tu Y, Gao M, Hanumegowda U, Knipe J, Lemm JA, Parker DD, Rigat KL, Roberts SB, Meanwell NA, Kadow JF.

Bioorg Med Chem Lett. 2016 Feb 1;26(3):936-940. doi: 10.1016/j.bmcl.2015.12.058. Epub 2015 Dec 19.

PMID:
26747393
3.

Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.

Sun JH, O'Boyle DR 2nd, Fridell RA, Langley DR, Wang C, Roberts SB, Nower P, Johnson BM, Moulin F, Nophsker MJ, Wang YK, Liu M, Rigat K, Tu Y, Hewawasam P, Kadow J, Meanwell NA, Cockett M, Lemm JA, Kramer M, Belema M, Gao M.

Nature. 2015 Nov 12;527(7577):245-8. doi: 10.1038/nature15711. Epub 2015 Nov 4.

PMID:
26536115
4.

Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.

Liu M, Tuttle M, Gao M, Lemm JA.

Antimicrob Agents Chemother. 2014 Dec;58(12):7416-23. doi: 10.1128/AAC.03851-14. Epub 2014 Sep 29.

5.

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.

Lemm JA, Liu M, Gentles RG, Ding M, Voss S, Pelosi LA, Wang YK, Rigat KL, Mosure KW, Bender JA, Knipe JO, Colonno R, Meanwell NA, Kadow JF, Santone KS, Roberts SB, Gao M.

Antimicrob Agents Chemother. 2014 Jun;58(6):3485-95. doi: 10.1128/AAC.02495-13. Epub 2014 Apr 14.

6.

Identification of a novel series of potent HCV NS5B Site I inhibitors.

Eastman KJ, Yang Z, Bender JA, Mosure K, Lemm JA, Meanwell NA, Roberts SB, Knipe J, Kadow JF.

Bioorg Med Chem Lett. 2014 Apr 15;24(8):1993-7. doi: 10.1016/j.bmcl.2014.02.047. Epub 2014 Feb 28.

PMID:
24656612
7.

Discovery and development of hepatitis C virus NS5A replication complex inhibitors.

Belema M, Lopez OD, Bender JA, Romine JL, St Laurent DR, Langley DR, Lemm JA, O'Boyle DR 2nd, Sun JH, Wang C, Fridell RA, Meanwell NA.

J Med Chem. 2014 Mar 13;57(5):1643-72. doi: 10.1021/jm401793m. Epub 2014 Feb 3.

PMID:
24621191
8.

Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.

Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR 2nd, Colonno RJ, Gao M, Meanwell NA, Hamann LG.

J Med Chem. 2014 Mar 13;57(5):2013-32. doi: 10.1021/jm401836p. Epub 2014 Feb 12.

PMID:
24521299
9.

Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.

Belema M, Nguyen VN, Romine JL, St Laurent DR, Lopez OD, Goodrich JT, Nower PT, O'Boyle DR 2nd, Lemm JA, Fridell RA, Gao M, Fang H, Krause RG, Wang YK, Oliver AJ, Good AC, Knipe JO, Meanwell NA, Snyder LB.

J Med Chem. 2014 Mar 13;57(5):1995-2012. doi: 10.1021/jm4016203. Epub 2014 Jan 17.

PMID:
24437689
10.

Characterizations of HCV NS5A replication complex inhibitors.

O'Boyle Ii DR, Sun JH, Nower PT, Lemm JA, Fridell RA, Wang C, Romine JL, Belema M, Nguyen VN, Laurent DR, Serrano-Wu M, Snyder LB, Meanwell NA, Langley DR, Gao M.

Virology. 2013 Sep;444(1-2):343-54. doi: 10.1016/j.virol.2013.06.032. Epub 2013 Jul 27.

11.

HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.

Belema M, Nguyen VN, St Laurent DR, Lopez OD, Qiu Y, Good AC, Nower PT, Valera L, O'Boyle DR 2nd, Sun JH, Liu M, Fridell RA, Lemm JA, Gao M, Knipe JO, Meanwell NA, Snyder LB.

Bioorg Med Chem Lett. 2013 Aug 1;23(15):4428-35. doi: 10.1016/j.bmcl.2013.05.040. Epub 2013 May 23.

PMID:
23803586
12.

HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.

St Laurent DR, Serrano-Wu MH, Belema M, Ding M, Fang H, Gao M, Goodrich JT, Krause RG, Lemm JA, Liu M, Lopez OD, Nguyen VN, Nower PT, O'Boyle DR 2nd, Pearce BC, Romine JL, Valera L, Sun JH, Wang YK, Yang F, Yang X, Meanwell NA, Snyder LB.

J Med Chem. 2014 Mar 13;57(5):1976-94. doi: 10.1021/jm301796k. Epub 2013 Apr 10.

PMID:
23573957
13.

Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.

Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, Voss S, Lemm JA, McPhee F.

Antimicrob Agents Chemother. 2013 Mar;57(3):1312-22. doi: 10.1128/AAC.02239-12. Epub 2012 Dec 28.

14.

HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.

Lopez OD, Nguyen VN, St Laurent DR, Belema M, Serrano-Wu MH, Goodrich JT, Yang F, Qiu Y, Ripka AS, Nower PT, Valera L, Liu M, O'Boyle DR 2nd, Sun JH, Fridell RA, Lemm JA, Gao M, Good AC, Meanwell NA, Snyder LB.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):779-84. doi: 10.1016/j.bmcl.2012.11.086. Epub 2012 Dec 3.

PMID:
23273521
15.

HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.

St Laurent DR, Belema M, Gao M, Goodrich J, Kakarla R, Knipe JO, Lemm JA, Liu M, Lopez OD, Nguyen VN, Nower PT, O'Boyle D 2nd, Qiu Y, Romine JL, Serrano-Wu MH, Sun JH, Valera L, Yang F, Yang X, Meanwell NA, Snyder LB.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6063-6. doi: 10.1016/j.bmcl.2012.08.049. Epub 2012 Aug 21.

PMID:
22959243
16.

Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.

Pelosi LA, Voss S, Liu M, Gao M, Lemm JA.

Antimicrob Agents Chemother. 2012 Oct;56(10):5230-9. doi: 10.1128/AAC.01209-12. Epub 2012 Jul 30.

17.

Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase.

Ding M, He F, Hudyma TW, Zheng X, Poss MA, Kadow JF, Beno BR, Rigat KL, Wang YK, Fridell RA, Lemm JA, Qiu D, Liu M, Voss S, Pelosi LA, Roberts SB, Gao M, Knipe J, Gentles RG.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2866-71. doi: 10.1016/j.bmcl.2012.02.063. Epub 2012 Mar 1.

PMID:
22424979
18.

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.

Qiu D, Lemm JA, O'Boyle DR 2nd, Sun JH, Nower PT, Nguyen V, Hamann LG, Snyder LB, Deon DH, Ruediger E, Meanwell NA, Belema M, Gao M, Fridell RA.

J Gen Virol. 2011 Nov;92(Pt 11):2502-11. doi: 10.1099/vir.0.034801-0. Epub 2011 Jul 27.

PMID:
21795470
19.

Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.

Lemm JA, Leet JE, O'Boyle DR 2nd, Romine JL, Huang XS, Schroeder DR, Alberts J, Cantone JL, Sun JH, Nower PT, Martin SW, Serrano-Wu MH, Meanwell NA, Snyder LB, Gao M.

Antimicrob Agents Chemother. 2011 Aug;55(8):3795-802. doi: 10.1128/AAC.00146-11. Epub 2011 May 16.

20.

Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.

Romine JL, St Laurent DR, Leet JE, Martin SW, Serrano-Wu MH, Yang F, Gao M, O'Boyle DR 2nd, Lemm JA, Sun JH, Nower PT, Huang XS, Deshpande MS, Meanwell NA, Snyder LB.

ACS Med Chem Lett. 2011 Jan 11;2(3):224-9. doi: 10.1021/ml1002647. eCollection 2011 Mar 10.

21.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG.

Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.

PMID:
20410884
22.

Identification of hepatitis C virus NS5A inhibitors.

Lemm JA, O'Boyle D 2nd, Liu M, Nower PT, Colonno R, Deshpande MS, Snyder LB, Martin SW, St Laurent DR, Serrano-Wu MH, Romine JL, Meanwell NA, Gao M.

J Virol. 2010 Jan;84(1):482-91. doi: 10.1128/JVI.01360-09.

23.

Replication-competent chimeric hepatitis C virus subgenomic replicons.

Lemm JA, Liu M, Rose RE, Fridell R, O'Boyle Ii DR, Colonno R, Gao M.

Intervirology. 2005;48(2-3):183-91.

PMID:
15812193
24.

Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.

O'Boyle DR 2nd, Nower PT, Lemm JA, Valera L, Sun JH, Rigat K, Colonno R, Gao M.

Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53.

25.

Specific inhibition of bovine viral diarrhea virus replicase.

Sun JH, Lemm JA, O'Boyle DR 2nd, Racela J, Colonno R, Gao M.

J Virol. 2003 Jun;77(12):6753-60.

26.

Template-dependent initiation of Sindbis virus RNA replication in vitro.

Lemm JA, Bergqvist A, Read CM, Rice CM.

J Virol. 1998 Aug;72(8):6546-53.

27.

Supplemental Content

Support Center